ZMYND8-targeting peptide PROTAC

ZMYND8-targeting peptide PROTAC is a peptide-based proteolysis-targeting chimera (PROTAC) designed to induce the degradation of the chromatin reader protein ZMYND8. This drug leverages the cell's natural ubiquitin-proteasome system by simultaneously binding to ZMYND8 and the E3 ubiquitin ligase MDM2, thereby facilitating the ubiquitination and subsequent proteasomal degradation of ZMYND8. Developed using AI-assisted protein structure prediction and macromolecular drug design, this PROTAC has demonstrated significant anti-acute myeloid leukemia (AML) activity in both in vitro and in vivo models. Its mechanism involves degrading ZMYND8, inhibiting cell proliferation, inducing apoptosis, and reducing c-Myc transcription. The drug also utilizes a nano-selenium delivery system to enhance its stability and membrane permeability.

Other names

ZMYND8 PROTAC drugZMYND-8 PROTAC drugZMYND 8 PROTAC drug